S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Question of whether Nebraska public money can go to private schools still set for November ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Question of whether Nebraska public money can go to private schools still set for November ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Question of whether Nebraska public money can go to private schools still set for November ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
How major US stock indexes fared Friday, 3/1/2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Question of whether Nebraska public money can go to private schools still set for November ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices

Abbott Laboratories (ABT) Competitors

$118.62
-0.02 (-0.02%)
(As of 03/1/2024 ET)

ABT vs. AZN, NVS, PFE, SNY, VRTX, REGN, BMY, ABBV, ZTS, and MRK

Should you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include AstraZeneca (AZN), Novartis (NVS), Pfizer (PFE), Sanofi (SNY), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceutical preparations" industry.

Abbott Laboratories vs.

Abbott Laboratories (NYSE:ABT) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.

Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 1.9%. AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 3.0%. Abbott Laboratories pays out 67.5% of its earnings in the form of a dividend. AstraZeneca pays out 100.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Abbott Laboratories has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Abbott Laboratories currently has a consensus price target of $120.00, suggesting a potential upside of 1.17%. AstraZeneca has a consensus price target of $80.00, suggesting a potential upside of 23.84%. Given AstraZeneca's higher possible upside, analysts plainly believe AstraZeneca is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69
AstraZeneca
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33

Abbott Laboratories received 860 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 69.48% of users gave Abbott Laboratories an outperform vote while only 58.24% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
Abbott LaboratoriesOutperform Votes
913
69.48%
Underperform Votes
401
30.52%
AstraZenecaOutperform Votes
53
58.24%
Underperform Votes
38
41.76%

73.7% of Abbott Laboratories shares are held by institutional investors. Comparatively, 15.7% of AstraZeneca shares are held by institutional investors. 1.1% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AstraZeneca has higher revenue and earnings than Abbott Laboratories. AstraZeneca is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$40.11B5.13$5.72B$3.2636.38
AstraZeneca$45.81B4.37$5.96B$1.9233.65

In the previous week, AstraZeneca had 9 more articles in the media than Abbott Laboratories. MarketBeat recorded 31 mentions for AstraZeneca and 22 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.81 beat AstraZeneca's score of 0.72 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abbott Laboratories
13 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AstraZeneca
13 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Abbott Laboratories has a net margin of 14.27% compared to AstraZeneca's net margin of 13.00%. AstraZeneca's return on equity of 30.19% beat Abbott Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Abbott Laboratories14.27% 20.65% 10.67%
AstraZeneca 13.00%30.19%11.57%

Summary

Abbott Laboratories beats AstraZeneca on 13 of the 20 factors compared between the two stocks.


Get Abbott Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABT vs. The Competition

MetricAbbott LaboratoriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$205.81B$6.73B$5.02B$17.49B
Dividend Yield1.83%2.84%2.81%3.57%
P/E Ratio36.388.91192.1021.78
Price / Sales5.13986.863,284.967.07
Price / Cash18.8719.1998.3616.03
Price / Book5.304.854.595.87
Net Income$5.72B$158.21M$114.86M$863.03M
7 Day Performance-0.71%7.52%5.65%1.62%
1 Month Performance5.79%15.77%11.15%3.17%
1 Year Performance15.57%7.92%13.97%100.99%

Abbott Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
2.8211 of 5 stars
$66.33
+0.6%
$80.00
+20.6%
-0.9%$205.65B$45.81B34.5583,500Short Interest ↑
Analyst Revision
NVS
Novartis
1.79 of 5 stars
$103.14
-0.1%
$104.33
+1.2%
+21.8%$218.62B$45.44B14.3676,057Dividend Increase
PFE
Pfizer
5 of 5 stars
$26.89
-1.1%
$36.88
+37.1%
-33.8%$151.84B$58.50B74.6988,000Analyst Report
Options Volume
SNY
Sanofi
3.46 of 5 stars
$48.21
+0.0%
$57.50
+19.3%
+0.6%$121.95B$46.61B20.4391,573Analyst Downgrade
VRTX
Vertex Pharmaceuticals
4.188 of 5 stars
$430.92
-0.6%
$417.27
-3.2%
+48.6%$111.31B$9.87B31.025,400Insider Selling
Short Interest ↑
Analyst Revision
REGN
Regeneron Pharmaceuticals
3.8206 of 5 stars
$993.35
+0.4%
$942.41
-5.1%
+27.6%$109.03B$13.12B28.5913,450Analyst Report
BMY
Bristol-Myers Squibb
4.7564 of 5 stars
$50.51
0.0%
$61.17
+21.1%
-26.6%$102.13B$45.01B13.0834,100Dividend Announcement
Analyst Upgrade
Analyst Revision
ABBV
AbbVie
4.8705 of 5 stars
$178.96
+0.1%
$175.36
-2.0%
+15.2%$316.12B$54.32B65.5550,000Insider Selling
Short Interest ↑
ZTS
Zoetis
4.7875 of 5 stars
$199.00
+1.0%
$224.33
+12.7%
+13.9%$91.12B$8.54B39.2514,100
MRK
Merck & Co., Inc.
4.7139 of 5 stars
$129.03
+0.1%
$130.12
+0.8%
+19.0%$326.96B$60.12B921.6469,000Analyst Report

Related Companies and Tools

This page (NYSE:ABT) was last updated on 3/2/2024 by MarketBeat.com Staff